Clovis Oncology, Inc.
CLVS
CLVS was delisted on the 20th of December, 2022.
0 hedge funds and large institutions have $0 invested in Clovis Oncology, Inc. in 2023 Q4 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, reducing their positions, and 1 closing their positions.
100% less funds holding
Funds holding: 1 → 0 (-1)
100% less capital invested
Capital invested by funds: $11K → $0 (-$11K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAS
Coppell Advisory Solutions
Coppell,
Texas
|
-$11K |
CLVS Hedge Fund Activity: Q4 2023 in Review
0 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Clovis Oncology, Inc. (CLVS) for Q4 2023, worth a combined $0 — down 100% from $11K a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of CLVS and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.
The largest seller was Coppell Advisory Solutions, exiting entirely with an estimated $11K sold.
- 0 institutional investors held Clovis Oncology, Inc. (CLVS) as of Q4 2023, down from 1 in Q3 2023.
- Funds reported $0 of Clovis Oncology, Inc. stock for Q4 2023, down 100% quarter-over-quarter.
- 0 funds opened new Clovis Oncology, Inc. positions in Q4 2023 and 1 closed out, a net change of -1 holder.
- The largest Clovis Oncology, Inc. seller in Q4 2023 was Coppell Advisory Solutions, an estimated $11K sold.
Based on aggregated 13F filings for Q4 2023.